Trial
NCT04613492
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
AstraZeneca
Collaborators
—
Condition
Solid Tumors
Intervention
MEDI9253
Why stopped
The study was terminated early due to lack of efficacy and absence of biomarker evidence of MEDI9253's impact on the tumors.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-24